Varina L Boerwinkle1, Stephen T Foldes2, Salvatore J Torrisi3, Hamy Temkit4, William D Gaillard5, John F Kerrigan1, Virendra R Desai6, Jeffrey S Raskin7, Aditya Vedantam7, Randa Jarrar1, Korwyn Williams1, Sandi Lam7, Manish Ranjan8, Janna S Broderson9, David Adelson1,8, Angus A Wilfong1, Daniel J Curry7. 1. Division of Pediatric Neurology, Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona. 2. Neuroscience Research, Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona. 3. Section on the Neurobiology of Fear and Anxiety, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. 4. Department of Research, Phoenix Children's Hospital, Phoenix, Arizona. 5. Department of Neurology, Children's National Medical Center, Washington, District of Columbia. 6. Department of Neurosurgery, Houston Methodist Hospital, Houston Methodist Neurological Institute, Houston, Texas. 7. Department of Pediatric Neurosurgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. 8. Division of Pediatric Neurosurgery, Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona. 9. Division of Pediatric Neurology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
Abstract
OBJECTIVE: The purpose of this study is to investigate the outcomes of epilepsy surgery targeting the subcentimeter-sized resting state functional magnetic resonance imaging (rs-fMRI) epileptogenic onset zone (EZ) in hypothalamic hamartoma (HH). METHODS: Fifty-one children with HH-related intractable epilepsy received anatomical MRI-guided stereotactic laser ablation (SLA) procedures. Fifteen of these children were control subjects (CS) not guided by rs-fMRI. Thirty-six had been preoperatively guided by rs-fMRI (RS) to determine EZs, which were subsequently targeted by SLA. The primary outcome measure for the study was a predetermined goal of 30% reduction in seizure frequency and improvement in class I Engel outcomes 1 year postoperatively. Quantitative and qualitative volumetric analyses of total HH and ablated tissue were also assessed. RESULTS: In the RS group, the EZ target within the HH was ablated with high accuracy (>87.5% of target ablated in 83% of subjects). There was no difference between the groups in percentage of ablated hamartoma volume (P = 0.137). Overall seizure reduction was higher in the rs-fMRI group: 85% RS versus 49% CS (P = 0.0006, adjusted). The Engel Epilepsy Surgery Outcome Scale demonstrated significant differences in those with freedom from disabling seizures (class I), 92% RS versus 47% CS, a 45% improvement (P = 0.001). Compared to prior studies, there was improvement in class I outcomes (92% vs 76%-81%). No postoperative morbidity or mortality occurred. SIGNIFICANCE: For the first time, surgical SLA targeting of subcentimeter-sized EZs, located by rs-fMRI, guided surgery for intractable epilepsy. Our outcomes demonstrated the highest seizure freedom rate without surgical complications and are a significant improvement over prior reports. The approach improved freedom from seizures by 45% compared to conventional ablation, regardless of hamartoma size or anatomical classification. This technique showed the same or reduced morbidity (0%) compared to recent non-rs-fMRI-guided SLA studies with as high as 20% permanent significant morbidity.
OBJECTIVE: The purpose of this study is to investigate the outcomes of epilepsy surgery targeting the subcentimeter-sized resting state functional magnetic resonance imaging (rs-fMRI) epileptogenic onset zone (EZ) in hypothalamic hamartoma (HH). METHODS: Fifty-one children with HH-related intractable epilepsy received anatomical MRI-guided stereotactic laser ablation (SLA) procedures. Fifteen of these children were control subjects (CS) not guided by rs-fMRI. Thirty-six had been preoperatively guided by rs-fMRI (RS) to determine EZs, which were subsequently targeted by SLA. The primary outcome measure for the study was a predetermined goal of 30% reduction in seizure frequency and improvement in class I Engel outcomes 1 year postoperatively. Quantitative and qualitative volumetric analyses of total HH and ablated tissue were also assessed. RESULTS: In the RS group, the EZ target within the HH was ablated with high accuracy (>87.5% of target ablated in 83% of subjects). There was no difference between the groups in percentage of ablated hamartoma volume (P = 0.137). Overall seizure reduction was higher in the rs-fMRI group: 85% RS versus 49% CS (P = 0.0006, adjusted). The Engel Epilepsy Surgery Outcome Scale demonstrated significant differences in those with freedom from disabling seizures (class I), 92% RS versus 47% CS, a 45% improvement (P = 0.001). Compared to prior studies, there was improvement in class I outcomes (92% vs 76%-81%). No postoperative morbidity or mortality occurred. SIGNIFICANCE: For the first time, surgical SLA targeting of subcentimeter-sized EZs, located by rs-fMRI, guided surgery for intractable epilepsy. Our outcomes demonstrated the highest seizure freedom rate without surgical complications and are a significant improvement over prior reports. The approach improved freedom from seizures by 45% compared to conventional ablation, regardless of hamartoma size or anatomical classification. This technique showed the same or reduced morbidity (0%) compared to recent non-rs-fMRI-guided SLA studies with as high as 20% permanent significant morbidity.
Authors: Pierre Bourdillon; S Ferrand-Sorbet; C Apra; M Chipaux; E Raffo; S Rosenberg; C Bulteau; N Dorison; O Bekaert; V Dinkelacker; C Le Guérinel; M Fohlen; G Dorfmüller Journal: Neurosurg Rev Date: 2020-04-21 Impact factor: 3.042
Authors: Karim Mithani; Alexandre Boutet; Jurgen Germann; Gavin J B Elias; Alexander G Weil; Ashish Shah; Magno Guillen; Byron Bernal; Justin K Achua; John Ragheb; Elizabeth Donner; Andres M Lozano; Elysa Widjaja; George M Ibrahim Journal: Sci Rep Date: 2019-12-09 Impact factor: 4.379
Authors: Nathan T Cohen; J Helen Cross; Alexis Arzimanoglou; Samuel F Berkovic; John F Kerrigan; Ilene Penn Miller; Erica Webster; Lisa Soeby; Arthur Cukiert; Dale K Hesdorffer; Barbara L Kroner; Clifford B Saper; Andreas Schulze-Bonhage; William D Gaillard Journal: Neurology Date: 2021-10-04 Impact factor: 9.910